Analysts expect Becton Dickinson and Co (NYSE:BDX) to report $2.60 earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Eight analysts have provided estimates for Becton Dickinson and’s earnings, with the highest EPS estimate coming in at $2.65 and the lowest estimate coming in at $2.54. Becton Dickinson and posted earnings of $2.30 per share during the same quarter last year, which suggests a positive year over year growth rate of 13%. The firm is expected to report its next quarterly earnings results on Tuesday, May 1st.
On average, analysts expect that Becton Dickinson and will report full-year earnings of $10.94 per share for the current year, with EPS estimates ranging from $10.85 to $11.00. For the next financial year, analysts anticipate that the firm will report earnings of $12.60 per share, with EPS estimates ranging from $12.44 to $12.86. Zacks’ earnings per share averages are an average based on a survey of sell-side analysts that cover Becton Dickinson and.
Becton Dickinson and (NYSE:BDX) last posted its earnings results on Tuesday, February 6th. The medical instruments supplier reported $2.48 EPS for the quarter, topping analysts’ consensus estimates of $2.41 by $0.07. Becton Dickinson and had a net margin of 2.71% and a return on equity of 16.19%. The business had revenue of $3.08 billion during the quarter, compared to the consensus estimate of $3.05 billion. During the same quarter in the previous year, the firm posted $2.33 EPS. The firm’s revenue was up 5.4% on a year-over-year basis.
A number of equities research analysts have commented on the stock. Bank of America reaffirmed a “buy” rating and issued a $260.00 target price on shares of Becton Dickinson and in a research report on Friday, January 19th. Zacks Investment Research raised shares of Becton Dickinson and from a “hold” rating to a “buy” rating and set a $259.00 target price for the company in a research report on Friday, January 19th. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $260.00 target price (up previously from $223.00) on shares of Becton Dickinson and in a research report on Tuesday, February 6th. Morgan Stanley lifted their target price on shares of Becton Dickinson and from $245.00 to $250.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 7th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and issued a $245.00 target price on shares of Becton Dickinson and in a research report on Friday, November 3rd. Four research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company’s stock. Becton Dickinson and currently has an average rating of “Buy” and an average target price of $237.27.
In other news, Director Timothy M. Ring sold 269,661 shares of the business’s stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $217.82, for a total transaction of $58,737,559.02. Following the completion of the sale, the director now owns 295,753 shares of the company’s stock, valued at approximately $64,420,918.46. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 1.00% of the company’s stock.
Hedge funds have recently modified their holdings of the company. Westwood Holdings Group Inc. lifted its stake in shares of Becton Dickinson and by 24.2% during the 2nd quarter. Westwood Holdings Group Inc. now owns 1,056,487 shares of the medical instruments supplier’s stock valued at $206,136,000 after buying an additional 205,721 shares in the last quarter. Colony Group LLC lifted its stake in shares of Becton Dickinson and by 2.1% during the 2nd quarter. Colony Group LLC now owns 11,889 shares of the medical instruments supplier’s stock valued at $2,320,000 after buying an additional 239 shares in the last quarter. State Street Corp lifted its stake in shares of Becton Dickinson and by 3.5% during the 2nd quarter. State Street Corp now owns 10,270,221 shares of the medical instruments supplier’s stock valued at $2,003,834,000 after buying an additional 342,873 shares in the last quarter. Peapack Gladstone Financial Corp lifted its stake in shares of Becton Dickinson and by 1.3% during the 2nd quarter. Peapack Gladstone Financial Corp now owns 36,472 shares of the medical instruments supplier’s stock valued at $7,116,000 after buying an additional 453 shares in the last quarter. Finally, Zions Bancorporation lifted its stake in shares of Becton Dickinson and by 23.7% during the 3rd quarter. Zions Bancorporation now owns 10,718 shares of the medical instruments supplier’s stock valued at $2,100,000 after buying an additional 2,050 shares in the last quarter. 77.50% of the stock is owned by hedge funds and other institutional investors.
Becton Dickinson and (NYSE:BDX) traded down $0.38 during trading hours on Friday, reaching $218.32. 793,230 shares of the company’s stock were exchanged, compared to its average volume of 1,580,000. The company has a debt-to-equity ratio of 1.04, a quick ratio of 0.93 and a current ratio of 1.54. Becton Dickinson and has a fifty-two week low of $175.66 and a fifty-two week high of $248.39. The company has a market cap of $58,130.00, a P/E ratio of 1,559.43, a PEG ratio of 1.57 and a beta of 1.12.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 30th. Stockholders of record on Friday, March 9th will be given a dividend of $0.75 per share. This represents a $3.00 dividend on an annualized basis and a dividend yield of 1.37%. The ex-dividend date of this dividend is Thursday, March 8th. Becton Dickinson and’s payout ratio is 2,142.86%.
COPYRIGHT VIOLATION NOTICE: This piece was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.dispatchtribunal.com/2018/02/22/becton-dickinson-and-co-bdx-expected-to-post-earnings-of-2-60-per-share.html.
Becton Dickinson and Company Profile
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.
Get a free copy of the Zacks research report on Becton Dickinson and (BDX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.